Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CMR.0000000000000610 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PD-L1, PD-1, and CTLA-4 mRNA In Situ Expression by Canine Oral Melanoma Cells and Immune Cells of the Tumour Microenvironment.
Vet Comp Oncol
January 2025
Histopathology Laboratory, Istituto Zooprofilattico Sperimentale delle Venezie, Padua, Italy.
Canine oral melanoma (OM) exhibits poor prognosis and limited treatment options. The success of immune checkpoint inhibitors (ICIs) in human melanoma has driven interest in similar therapeutic approaches in the dog, although the immunosuppressive mechanisms adopted by canine OM remain unclear. This study aimed to evaluate the expression of the immune checkpoints PD-1/PD-L1 and CTLA-4 by RNAscope in situ hybridization (ISH) in canine OM, to investigate their expression pattern and explore their potential role in melanoma progression.
View Article and Find Full Text PDFCanine Adipose-Derived Mesenchymal Stromal Cells Reduce Cell Viability and Migration of Metastatic Canine Oral Melanoma Cell Lines In Vitro.
Vet Sci
December 2024
Department of Veterinary Surgery and Animal Reproduction, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu 18618-681, Brazil.
Canine oral melanoma (COM) is a promising target for immunomodulatory therapies aimed at enhancing the immune system's antitumor response. Given that adipose-derived mesenchymal stem cells (Ad-MSCs) possess immunomodulatory properties through cytokine release, we hypothesized that co-culturing Ad-MSCs and canine peripheral blood mononuclear cells (PBMCs) could stimulate interleukin (IL) production against melanoma cell lines (MCCLs) and help identify therapeutic targets. This study evaluated IL-2, IL-8, and IL-12 expressions in co-culture with MCCL, Ad-MSCs, and PBMCs and assessed the relationship between gene expression, cell viability, and migration.
View Article and Find Full Text PDFAPAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma.
Vet Sci
December 2024
Ospedale Veterinario I Portoni Rossi, Anicura Italy Holding, via Roma 51, 40069 Zola Predosa, Italy.
An 11-year-old spayed female Beagle presented with tenesmus and was identified with a rectal wall mass. Diagnostic imaging (abdominal ultrasound and computed tomography) localised the mass in the right rectal wall and documented no evidence of metastatic disease. Subsequently, the dog underwent surgery for tumour excision.
View Article and Find Full Text PDFPreclinical evaluation of an anchored immunotherapy strategy with aluminum hydroxide-tethered interleukin-12 in dogs with advanced malignant melanoma.
Mol Cancer Ther
December 2024
University of Illinois Urbana-Champaign, Urbana, Illinois, United States.
Article Synopsis
- * The study focused on JEN-101, a localized injection of interleukin-12 designed to boost immune response in dogs with advanced melanoma, evaluating its safety, effectiveness, and immune effects over several doses.
- * Results indicated that JEN-101 was well-tolerated with manageable side effects, and it showed promising biological responses, suggesting its potential for further research and relevance to human cancer treatment.
Response of Spontaneous Oral Tumors in Canine Cancer Patients Treated with Stereotactic Body Radiation Therapy (SBRT).
Radiat Res
December 2024
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado.
The objective of this study is describe outcome and toxicity for dogs with oral tumors, specifically oral malignant melanoma (OMM), squamous cell carcinoma (SCC), and soft tissue sarcoma (STS) after stereotactic body radiation therapy (SBRT). A single institution retrospective study was conducted. Outcomes were analyzed using Kaplan-Meier analysis and Cox proportional hazard analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!